AbbVie Inc. (BIT:1ABBV)

Italy flag Italy · Delayed Price · Currency is EUR
160.00
0.00 (0.00%)
Last updated: Jul 22, 2025
Market Cap281.60B
Revenue (ttm)53.08B
Net Income (ttm)3.84B
Shares Outn/a
EPS (ttm)2.16
PE Ratio73.25
Forward PE15.04
Dividend4.27 (2.67%)
Ex-Dividend DateJul 14, 2025
Volumen/a
Average Volume9
Open160.00
Previous Close160.00
Day's Range160.00 - 160.00
52-Week Range149.00 - 202.55
Betan/a
RSI44.29
Earnings DateJul 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 55,000
Stock Exchange Borsa Italiana
Ticker Symbol 1ABBV
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements

News

There is no news available yet.